STOCK TITAN

Bionexus Gene La (BGLC) Debt by Year

BGLC

Bionexus Gene La held $2.4M in cash and equivalents at the end of fiscal year 2025, and long-term debt is not reported for that period. The table below carries 8 fiscal years, from 2018 to 2025, and the quarters Bionexus Gene La has filed alongside them.

FY2025 annual
Long-Term Debt N/A
Cash & Equivalents $2.4M
Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Currency USD

Annual figures, oldest first. Point at a bar to read its period.

BGLC Debt & Cash by Fiscal Year

Figures are as reported in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.

MetricFY2510-KFY2410-KFY2310-KFY2210-KFY2110-KFY2010-KFY1910-KFY1810-K
Long-Term DebtN/AN/AN/AN/AN/AN/AN/AN/A
Cash & Equivalents$2.4M-17.4%$2.9M-36.1%$4.5M+113.2%$2.1M-0.2%$2.1M-23.8%$2.8M+224.5%$859K-31.8%$1.3M

BGLC Debt & Cash by Quarter

Figures are as reported in USD. Each change compares the quarter with the same quarter a year earlier.

MetricQ2'2610-QQ1'2610-QQ4'2510-QQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-KQ3'2410-QQ2'2410-QQ1'2410-QQ4'2310-KQ3'2310-Q
Long-Term DebtN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
Cash & Equivalents$1.2M-19.8%$1.3M-36.0%$2.4M-17.4%$1.2M-72.1%$1.5M-71.6%$2.1M-52.9%$2.9M-36.1%$4.1M-32.7%$5.4M+207.8%$4.4M+124.9%$4.5M+113.2%$6.1M+320.4%

What long-term debt means

Long-term debt is borrowing that falls due more than a year out, and the cash line beside it is what the company held on the same balance sheet date.

More Bionexus Gene La financials

Frequently Asked Questions

What was Bionexus Gene La's long-term debt in fiscal year 2025?

Bionexus Gene La held $2.4M in cash and equivalents at the end of fiscal year 2025, and long-term debt is not reported for that period.

What does long-term debt mean on a financial statement?

Long-term debt is borrowing that falls due more than a year out, and the cash line beside it is what the company held on the same balance sheet date. This page lists what Bionexus Gene La (BGLC) reported on that line in every period on record.